Drug-induced scleroderma and sclerodermiform conditions

Clinics in Dermatology

Volumn 16, Issue 3, 1998, Pages 353-366

  Haustein, Uwe Frithjof ^a,b   Haupt, Bettina ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Department of Dermatology ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMFEPRAMONE; ANALGESIC AGENT; ANOREXIGENIC AGENT; ANTINEOPLASTIC AGENT; ANTINUCLEAR ANTIBODY; BISOPROLOL; BLEOMYCIN; BROMOCRIPTINE; CARBIDOPA; COCAINE; CYTOKINE; DOCETAXEL; ERGOT ALKALOID; ETHOSUXIMIDE; FOSINOPRIL; GLUCOCORTICOID; GROWTH FACTOR; KETANSERIN; KETOGAN; METHYSERGIDE; NEUROTRANSMITTER; PENICILLAMINE; PENTAZOCINE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; TRIAMCINOLONE; TRYPTOPHAN; UNINDEXED DRUG; VITAMIN K GROUP;

ANAPHYLAXIS; CHRONIC PAIN; CLINICAL TRIAL; EOSINOPHILIA MYALGIA SYNDROME; EPILEPSY; FIBROBLAST; HUMAN; HYPOPHYSIS ADENOMA; IMMUNE SYSTEM; INSOMNIA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG FIBROSIS; MELANOMA; MORPHEA; NONHUMAN; OBESITY; PRIORITY JOURNAL; PUVA; REVIEW; SCLERODERMA; SKIN BIOPSY; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; ULTRAVIOLET A RADIATION; URTICARIA;

EID: 0032077242     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(98)00006-6     Document Type: Article

References (82)

1. 1. Fishman SJ, Russo GG. The toxic pseudosclerodermas. Int J Dermatol 1991;30:837-42.
2. 2. Haustein U-F, Herrmann K. Environmental scleroderma. Clin Dermatol 1994;12:467-73.
3. 3. Haustein U-F, Ziegler V, Herrmann K, et al. Silica-induced scleroderma. J Am Acad Dermatol 1990;22:444-8.
4. 4. Rustin MHA, Bull HA, Ziegler V, et al. Silica-associated systemic sclerosis is clinically, serologically indistinguishable from idiopathic systemic sclerosis. Br J Dermatol 1990;123:725-34.
5. 5. Cohen IS, Mosher MB, O'Keefe EJ, et al. Cutaneous toxicity of bleomycin therapy. Arch Dermatol 1973;107:553-5.
6. 6. Bork K, Korting GW. Symptomatische Sklerodermie durch Bleomyzin. Hautarzt 1983;34:10-12.
7. 7. Snauwaert J, Degreef H. Bleomycin-induced Raynaud's phenomenon and acral sclerosis. Dermatologica 1984;169: 172-4.
8. 8. Finch WR, Rodnan GP, Buckingham RB, et al. Bleomycin-induced scleroderma. J Rheumatol 1980;7:651-9.
9. 9. Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: A report of 3 cases. J Rheumatol 1992; 19:294-6.
10. 10. Otouka K, Murota S, Mori Y. Stimulatory effect of bleomycin on the synthesis of acidic glycosaminoglycans in cultured fibroblasts derived from rat carrageenan granuloma. Biochim Biophys Acta 1976;444:359-68.
11. 11. Marck Y, Meunier L, Barnéon G, et al. Sclerose cutanee en pelerine au decours d'un traitement par l'association bleomycine et radiotherapie. Ann Dermatol Venereol 1994; 121:712-4.
12. 12. Varga J, Haustein U-F, Creech RH, et al. Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA 1991;265:3292-5.
13. 13. Aref I, Cross P, Nair B. Case report: Severe fibrosis in a patient with scleroderma and previous radiotherapy - a case report and literature review. Br J Radiol 1996;69: 1055-6.
14. 14. Mountz JD, Downs Minor MB, Turner R, et al. Bleomycin-induced cutaneous toxicity in the rat: Analysis of histopathology and ultrastructure compared with progressive systemic sclerosis (scleroderma). Br J Dermatol 1983;108: 679-86.
15. 15. Clark JG, Starcher BC, Uitto J. Bleomycin-induced synthesis of type I procollagen by human lung and skin fibroblasts in culture. Biochim Biophys Acta 1980;631:359-70.
16. 16. Zhang HY, Gharaee-Kermani M, Zhang K, et al. Lung fibroblast alpha-smooth muscle actin expression and contractile phenotype in bleomycin-induced pulmonary fibrosis. Am J Pathol 1996;148:527-37.
17. 17. Maeda A, Hiyama K, Yamakido H, et al. Increased expression of platelet-derived growth factor-A and insulin-like growth factor-I in BAL cells during the development of bleomycin-induced pulmonary fibrosis in mice. Chest 1996;109:780-6.
18. 18. Zimmermann GC, Keeling JH, Burris HA, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995;131:202-6.
19. 19. Extra JM, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of taxotere (RP56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993; 53:1037-42.
20. 20. Battafarano DF, Zimmerman GC, Older SA, et al. Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities: A report of three cases. Cancer 1995;76:110-5.
21. 21. Palestine RF, Millns JL, Spigel GT, et al. Skin manifestations of pentazocine abuse. J Am Acad Dermatol 1980;2: 47-55.
22. 22. Hertzman A, Toone E, Resnik CS. Pentazocine-induced myocutaneous sclerosis. J Rheumatol 1986;13:210-4.
23. 23. Bonnie BF. Parenteral pentazocine: Cutaneous complications revisited. J Am Acad Dermatol 1990;22:694-5.
24. 24. Kim HA, Song YW. Polymyositis developing after prolonged injections of pentazocine. J Rheumatol 1996;23: 1644-6.
25. 25. Bellmann B, Berman B. Localized indirated brown plaques on arms and right buttock: Pentazocine-induced morphea. Arch Dermatol 1996;132:1366-7, 1368-9.
26. 26. Parks DL, Perry HO, Muller SA. Cutaneous complications of pentazocine injections. Arch Dermatol 1971;104:231-5.
27. 27. Goldberg NC, Duncan SC, Winkelmann RK. Migraine and systemic scleroderma. Arch Dermatol 1978;114:550-1.
28. 28. Coffman JD, Davies WT. Vasospastic diseases: A review. Prog Cardiovasc Dis 1975;18:123-46.
29. 29. Graham JR. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci 1967;254: 1-12.
30. 30. Kottra JJ, Dunnick NR. Retroperitoneal fibrosis. Radiol Clin North Am 1996;34:1259-75.
31. 31. Leshin B, Piette WW, Caplan RM. Morphea after bromocriptine therapy. Int J Dermatol 1989;28:177-9.
32. 32. Rinne UK. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease. Lancet 1981;3:44-5.
33. 33. Le Witt PA, Calne DB. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease. Lancet 1981;3:44-5.
34. 34. Dupont E, Olivarius B, Strong MJ. Bromocriptine-induced collagenosis-like symptomatology in Parkinson's disease. Lancet 1982;1:850-1.
35. 35. Danielsen AG, Hultberg IB, Weismann K. Skin lesions after injection abuse: Chronic changes caused by ketobemidone (Ketogan). Ugreskr Laeger 1994;156:162-4.
36. 36. Rasmussen YH, Thomsen AB. Cutaneous symptoms after continuous subcutaneous injection of morphine. Ugeskr Laeger 1996;158:3623-4.
37. 37. Centers for Disease Control. Eosinophilia-myalgia syndrome: New Mexico. MMWR 1989;38:765-7.
38. 38. Varga J, Peltonen J, Uitto J, et al. Development of diffuse fasciitis with eosinophilia during L-tryptophan treatment: Demonstration of elevated type I collagen gene expression in affected tissues. Ann Intern Med 1990;112:344-51.
39. 39. Mensing H. L-Tryptophan ingestion does not induce progressive systemic sclerosis (scleroderma). Dermatology 1992;185:173-4.
40. 40. Morgan JM, Adams SJ. Scleroderma and autoimmune thrombocytopenia associated with ingestion of L-tryptophan. Br J Dermatol 1993;128:581-3.
41. 41. Varga J, Jimenez SA, Uitto J. L-Tryptophan and the eosinophilia-myalgia syndrome: Current understanding of the etiology and pathogenesis. J Invest Dermatol 1993;100: 97S-105S.
42. 42. Belongia EA, Hedberg CW, Gleich GJ, et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 1990;323: 357-65.
43. 43. Mayeno AN, Lin F, Foote CS, et al. Characterization of 'peak E', a novel amino acid associated with eosinophilia-myalgia syndrome. Science 1990;250:1707-8.
44. 44. Crofford LJ, Rader JI, Dalakas MC, et al. L-Tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in Lewis rat. J Clin Invest 1990;86:1757-63.
45. 45. Yamaoka KA, Miyasaka N, Kashiwasaki S. L-Tryptophan contaminant 'peak E' and interleukin-5 production from T cells. Lancet 1991;338:1468.
46. 46. Suzuki S, Tourkina E, Ludwicka A, et al. A contaminant of L-tryptophan enhances expression of dermal collagen in a murine model of eosinophilia-myalgia syndrome. Proc Assoc Am Physicians 1996;108:315-22.
47. 47. Varga J, Li L, Jimenez SA. Increased type I collagen gene expression in L-tryptophan-associated eosinophilia-myalgia syndrome skin fibroblasts. J Rheumatol 1993;20: 1303-8.
48. 48. Silver RM, Heyes MP, Maize JC, et al. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med 1990;22:874-81.
49. 49. Kaufman LD, Seidman RJ, Phillips ME, et al. Cutaneous manifestations of the L-tryptophan-associated eosinophilia-myalgia syndrome: A spectrum of sclerodermatous skin disease. J Am Acad Dermatol 1990;23:1063-9.
50. 50. Silver RM. Pathophysiology of the eosinophilia-myalgia syndrome. J Rheumatol 1996;23:26-36.
51. 51. Kirsner RS, Pardes JB, Falanga V. L-Tryptophan-associated progressive systemic sclerosis. Eur J Dermatol 1992; 2:549-51.
52. 52. Sternberg EM, Van Woert MH, Young SN, et al. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med 1980;303:782-7.
53. 53. Auffranc JC, Berbis P, Fabre JF, et al. Syndrome sclérodermiforme et poikilodermique observé au cours d'un traitement par carbidopa et 5-hydroxy-tryptophanne. Ann Dermatol Venereol 1985;112:691-2.
54. 54. Lampert A, Joly P, Thomine E, et al. Syndrome sclerodermiforme a type de morphees bulleuses au cours d'un traitement par 5-hydroxy-tryptophane, carbidopa et flunitrazepam. Ann Dermatol Venereol 1992;119:209-11.
55. 55. Zarafonetis CJD, Lorber SH, Hanson SM. Association of functioning carcinoid syndrome and scleroderma. Am J Med Sci 1958;236:1-14.
56. 56. Stachów A, Jablonska S, Skiendzielewska A. Biogenic amines derived from tryptophan in systemic and cutaneous scleroderma. Acta Derm Venerol 1979;59:1-5.
57. 57. Teoh PC, Chan HL. Lupus-scleroderma syndrome induced by ethosuximide. Arch Dis Child 1975;50:658-61.
58. 58. Tomlinson IW, Jay son MIV. Systemic sclerosis after therapy with appetite suppressants. J Rheumatol 1984;11:254.
59. 59. Aeschlimann A, de Truchis P, Kahn MF. Scleroderma after therapy with appetite suppressants. Scand J Rheumatol 1990;19:87-90.
60. 60. Thomas SH, Butt AY, Corris PA, et al. Appetite suppressants and primary pulmonary hypertension in the United Kingdom. Br Heart J 1995;74:660-3.
61. 61. Cacoub P, Dorent R, Nataf P, et al. Pulmonary hypertension and dexfenfluramine (letter). Eur J Clin Pharmacol 1995;48:81-3.
62. 62. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335:609-16.
63. 63. Weir EK, Reeve HL, Huang JM, et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996; 94:2216-20.
64. 64. Sanders MN, Winkelmann RK. Cutaneous reactions to vitamin K. J Am Acad Dermatol 1988;19:699-704.
65. 65. Texier L, Gendre PH, Gauthier O, et al. Hypodermites sclérodermiformes lombo-fessières induites par des injections médicamenteuses intramusculaires associées a la vitamine K1. Ann Dermatol Venereol 1972;99:363-71.
66. 1) injections. Cutis 1989;43:365-8.
67. 67. Morell A, Betlloch I, Sevila A, et al. Morphea-like reaction from vitamin K1. Int J Dermatol 1995;34:201-2.
68. 1 injections. Contact Dermatitis 1994;31:45-62.
69. 69. Janin-Mercier A, Mosser C, Souteyrand P, et al. Subcutaneous sclerosis with fasciitis and eosinophilia after phytonadione injections. Arch Dermatol 1985;121:1421-3.
70. 70. Larregue M, Auriol F, Vabres P. Induction of sclerodermiform hypodermitis by vitamin K1 in newborns: A report of nine cases. J Eur Acad Dermatol Venereol 1996;7: 579.
71. 71. Miyagawa S, Yoshioka A, Hatoko M, et al. Systemic sclerosis-like lesions during long-term penicillamine therapy for Wilson's disease. Br J Dermatol 1987;116:95-100.
72. 72. Sasaki T, Denpo K, Ono H, et al. Nodular scleroderma in systemic sclerosis under D-penicillamine therapy. J Dermatol 1992;19:968-71.
73. 73. Liddle BJ. Development of morphea in rheumatoid arthritis treated with penicillamine. Ann Rheum Dis 1989;48:963-4.
74. 74. Bernstein RM, Hall MA, Gostelow BE. Morphea-like reaction to D-penicillamine therapy. Ann Rheum Dis 1981; 40:42-4.
75. 75. De Dobbeleer G, Engelholm JL, Heenen M. Morphea after beta-blocker therapy. Eur J Dermatol 1993;3:108-9.
76. 76. Berg R, Moss J, Baum B, et al. Regulation of collagen production by the beta-adrenergic system. J Clin Invest 1981;67:1457-62.
77. 77. Biasi D, Caramaschi P, Carletto A, et al. Scleroderma and eosinophilic fasciitis in patients taking fosinopril. J Rheumatol 1997;24:1242.
78. 78. Rodriguez-Prieto MA, Quinones PA, Aragoneses H, et al. Sclerodermiform linear atrophy caused by triamcinolone. Med Cutan Ibero Lat Am 1985;13:353-6.
79. 79. Böni R, Dummer R, Burg G. Acral sclerosis and leukoderma in a melanoma patient treated with interferon-alpha and interleukin-2. Eur J Dermatol 1995;5:383-5.
80. 80. Kerr HD. Cocaine and scleroderma. South Med J 1989;82: 1275-6.
81. 81. Kilaru P, Kim W, Sequeira W. Cocaine and scleroderma: Is there an association? J Rheumatol 1991;18:1753-5.
82. 82. Ritchie JM, Greene NM. Local anesthetics. In: Gilman AG, Goodman LS, Rall TW, Murad F, editors. The pharmacological basis of therapeutics, 7th ed. New York: Macmillan, 1985:309-10.